GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non-drug care up front.
|Articles|July 16, 2012
Analysis: U.S. Governors Make Risky Political Bet on Healthcare Funds
Advertisement
Republican governors bent on rejecting the healthcare law's expanded insurance coverage for millions of low-income Americans may see their gambit backfire if their party fails to sweep the November elections.
Five governors have vowed to opt out of the Medicaid expansion for low-income people since the Supreme Court's June 28 landmark healthcare ruling let states decide whether to participate in the program. Several others, saying the program will be a huge financial burden on states, are leaning toward the same action.
Read the full story:
Source: Chicago Tribune
Advertisement
Related to this article
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
4
Health Equity & Access Weekly Roundup: November 6, 2026
5